desperate!, page-2

Anyone who invests in a biotech should know the commercialisation process is a long and often difficult process to progress from Phase II to Phase III and then FDA approval and product launch. It's frustrating that Mesoblast has seen delays in the past couple of years and a flagging shareprice but this is a long term play and management have been systematically putting the pieces in play to develop a future giant.

The science is amazing, they have impressive results across the scope of treatments including major medical issues (=$$$) including heart failure, stroke, spinal injury. The company have IP protection; $ in the bank; strategic partnerships for commercialisation and manufacturing; and a detailed plan for long term success.
Mesoblast have 5 or 6 treatments at Phase III trials and another 6-8 in Phase II. If Mesoblast proves successful, our company will revolutionalise medical treatment.

There is no guarantee of success but if all goes to plan in 5 years time the shareprice will be many multiples of where it is now. Patience needed - the low share price is an opportunity for long term holders